What is Replimune Group's R&D?

Replimune Group (REPL) reported R&D of $53.14M in Q4 2025.

How has Replimune Group's R&D changed year-over-year?

Replimune Group's R&D increased by 10.7% year-over-year, from $48M to $53.14M.

What is the long-term trend for Replimune Group's R&D?

Over 3 years (2022 to 2025), Replimune Group's R&D has grown at a 33.3% compound annual growth rate (CAGR), from $79.55M to $188.4M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Replimune Group REPL R&D

R&D at other companies

AmgenAMGN

$1.72B+15.7%

Regeneron PharmaceuticalsREGN

$1.54B+16.3%

Inhibrx Biosciences, Inc.INBX

$25.22M-31.6%

ImmunomeIMNM

$46.38M+25.8%

CG OncologyCGON

$43.73M+59.2%

Erasca, Inc.ERAS

$27.27M+5.0%

Other financials

Income statement

See full

Operating income-$71.9M-8.9%

Net income-$70.9M-6.9%

EPS (diluted)-$0.77+2.5%

Balance sheet

See full

Cash & equivalents$124.7M-28.3%

Total debt$79.2M+0.5%

Total equity$210.5M-56.4%

Total assets$333.6M-44.7%

Cash flow

See full

Operating cash flow-$66.0M-30.1%

CapEx$135.0K-92.5%

Free cash flow-$66.1M-25.9%

Valuation

See full

Market cap$930.59M+30.2%

Enterprise value$885.15M+30.0%

Returns & leverage

See full

Return on equity-90.9%+362pp

Debt / equity0.4×+0.2×

Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Replimune Group's R&D?: Replimune Group (REPL) reported R&D of $53.14M in Q4 2025.
How has Replimune Group's R&D changed year-over-year?: Replimune Group's R&D increased by 10.7% year-over-year, from $48M to $53.14M.
What is the long-term trend for Replimune Group's R&D?: Over 3 years (2022 to 2025), Replimune Group's R&D has grown at a 33.3% compound annual growth rate (CAGR), from $79.55M to $188.4M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.